OptimizeRx Reports First Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance
OptimizeRx Corp. reported Q1 2026 revenue of $19.8 million, a 10% decrease year-on-year, but achieved a narrowed GAAP net loss of $0.5 million and increased adjusted EBITDA to $3.3 million. The company updated its fiscal year 2026 revenue guidance higher to $95-$100 million while maintaining adjusted EBITDA guidance at $21-$25 million. Subsequent t…